ANGLE Shares University Research Results Studying Parsortix

ANGLE plc (AIM:AGL; OTCQX:ANPCY) announced the University of Southern California (USC) Norris Comprehensive Cancer Center presented new results from its research work with ANGLE’s Parsortix system.
As quoted in the press release:

USC made a direct comparison of extensive gene expression information from the biopsy of the metastatic site with that from a blood test processed with the Parsortix system. Information from the blood test using the Parsortix system “did not show significantly different patterns of expression” compared to the invasive biopsy of the metastatic site. 66 clinically actionable genes in 7 different signalling pathways were measured addressing the key areas that clinicians currently investigate.
ANGLE is working towards an FDA clearance of the Parsortix system in metastatic breast cancer with the required analytical and clinical studies targeted for completion by 30 June 2018. ANGLE is seeking to become the first company ever to receive FDA clearance for a medical device to harvest cancer cells from patient blood for subsequent analysis. The ground-breaking work presented by USC at SABCS demonstrates the importance of being able to harvest and analyse these cells from patient blood.

Click here to read the full press release.

Source: www.marketwired.com